Explore Products

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

  • AcceGen R&D Team
  • Jul 27, 2023
  • 25

You Might Also Like

AcceGen Scroll Top Button